nanaxbf.blogg.se

The heterologous chimeric protein of claim 49, wherein the Heterologous chimeric protein is capable of providing a sustainedĥ9. Heterologous chimeric protein is capable of enhancing tumor killingĥ8. Preventing a decrease in a sub-population of CD4+ and/or CD8+ Tĥ7. Heterologous chimeric protein is capable of increasing or PD-L1 or PD-L2 and the 4-1BBL receptor is 4-1BB.ĥ6. The PD-1 ligand and the 4-1BBL receptor, wherein the PD-1 ligand is Heterologous chimeric protein is capable of simultaneously binding

The heterologous chimeric protein of claim 49, wherein theĥ5. The heterologous chimeric protein of claim 49, wherein the PD-1ĥ4. Stimulatory signal when the portion of 4-1BBL is bound to itsĥ3. Heterologous chimeric protein is capable of: (a) reducing orĮliminating an immune inhibitory signal when the portion of PD-1 isīound to its ligand and/or (b) increasing or activating an immune Heterologous chimeric protein is capable of inhibiting anĥ2. The heterologous chimeric protein of claim 49, wherein theįirst domain comprises substantially all of the extracellularĭomain of PD-1 and the second domain comprises substantially all ofĥ1. Second domain and comprising a hinge-CH2-CH3 Fc domain.ĥ0. Is capable of binding a PD-1 ligand, (b) a second domain comprisingĪ portion of 4-1BB ligand (4-1BBL) that is capable of binding aĤ-1BBL receptor, and (c) a linker linking the first domain and the A heterologous chimeric protein comprising: (a) a first domainĬomprising a portion of programmed cell death protein 1 (PD-1) that Part, the invention provides, in various embodiments, fusions ofĮxtracellular domains of transmembrane proteins that can have Of disease, such as immunotherapies for cancer and autoimmunity. Methods, including chimeric proteins that find use in the treatment

The present invention relates to, inter alia, compositions and Invention is credited to Suresh DE SILVA, George FROMM, Neal SCHILLING, Taylor SCHREIBER.ĬOMPOSITIONS AND METHODS FOR ADJOINING TYPE I AND TYPE IIĮXTRACELLULAR DOMAINS AS HETEROLOGOUS CHIMERIC PROTEINS The applicant listed for this patent is Heat Biologics, Inc. patent application number 16/024218 was filed with the patent office on for compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins.